{
    "organizations": [],
    "uuid": "2ecfac1cf35d49c669e6fc7adedfeacc49074c58",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/26/globe-newswire-2018-first-half-year-financial-results-webcast-for-mesoblast.html",
    "ord_in_thread": 0,
    "title": "2018 First Half Year Financial Results Webcast for Mesoblast",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NEW YORK and MELBOURNE, Australia, Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first half year ended December 31, 2017 in a webcast beginning at 4:30 pm EST on Tuesday, February 27, 2018; 8:30 am Wednesday, February 28, 2018 AEDT.\nThe live webcast can be accessed via\nhttp://webcasting.brrmedia.com/broadcast/5a6ffa22271b41638bdc2f22\nTo access the call only, dial 1 855 881 1339 (U.S.), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the U.S. and Australia). The conference identification code is 882151.\nThe archived webcast will be available on the Investor page of the Company’s website – www.mesoblast.com\nAbout Mesoblast\nMesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.\nFor further information, please contact:\nJulie Meldrum\nCorporate Communications\nMesoblast Limited\nT: +61 3 9639 6036\nE: julie.meldrum@mesoblast.com\nSchond Greenway\nInvestor Relations\nMesoblast Limited\nT: +1 212 880 2060\nE: schond.greenway@mesoblast.com\nSource:Mesoblast Limited",
    "published": "2018-02-27T00:00:00.000+02:00",
    "crawled": "2018-02-27T01:13:22.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "new",
        "york",
        "melbourne",
        "australia",
        "mesoblast",
        "limited",
        "nasdaq",
        "meso",
        "asx",
        "msb",
        "today",
        "announced",
        "report",
        "financial",
        "result",
        "first",
        "half",
        "year",
        "ended",
        "december",
        "webcast",
        "beginning",
        "pm",
        "est",
        "tuesday",
        "february",
        "wednesday",
        "february",
        "aedt",
        "live",
        "webcast",
        "accessed",
        "via",
        "http",
        "access",
        "call",
        "dial",
        "australia",
        "outside",
        "australia",
        "conference",
        "identification",
        "code",
        "archived",
        "webcast",
        "available",
        "investor",
        "page",
        "company",
        "website",
        "mesoblast",
        "mesoblast",
        "limited",
        "nasdaq",
        "meso",
        "asx",
        "msb",
        "global",
        "leader",
        "developing",
        "innovative",
        "medicine",
        "company",
        "leveraged",
        "proprietary",
        "technology",
        "platform",
        "based",
        "specialized",
        "cell",
        "known",
        "mesenchymal",
        "lineage",
        "adult",
        "stem",
        "cell",
        "establish",
        "broad",
        "portfolio",
        "product",
        "candidate",
        "mesoblast",
        "allogeneic",
        "cell",
        "product",
        "candidate",
        "target",
        "advanced",
        "stage",
        "disease",
        "high",
        "unmet",
        "medical",
        "need",
        "including",
        "cardiovascular",
        "disease",
        "inflammatory",
        "disorder",
        "orthopedic",
        "disorder",
        "condition",
        "information",
        "please",
        "contact",
        "julie",
        "meldrum",
        "corporate",
        "communication",
        "mesoblast",
        "limited",
        "e",
        "schond",
        "greenway",
        "investor",
        "relation",
        "mesoblast",
        "limited",
        "e",
        "source",
        "mesoblast",
        "limited"
    ]
}